Heron Therapeutics, Inc. (HRTX)

2.0900 +0.0200 (+0.96%) As of 02:13PM EDT. Market open.

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 126

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Craig Alexander Collard	CEO & Director	5.49k	N/A	1966
Ms. Ira Duarte	Executive VP & CFO	636.89k	N/A	1969
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer	734.62k	N/A	1962
Mr. Ryan Craig	Vice President of Marketing	N/A	N/A	N/A
Mr. Sean T. Ristine	Senior Vice President of Human Resources	N/A	N/A	1970
Mr. Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations	N/A	N/A	1978
Mr. Brett Fleshman	Chief Business Officer	N/A	N/A	N/A
Jeff Cohn	Executive Director, Assistant General Counsel & Assistant Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate governance

Heron Therapeutics, Inc.’s ISS governance QualityScore as of 1 October 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.